Slide 1: Agilent Technologies Q2'23 Financial Results Overview
Agilent Technologies Q2’23 Financial Results Overview
Slide 2: Safe Harbor
Safe Harbor These presentations contain forward-looking statements (including, without limitation, information, and future guidance on the company’s goals, priorities, revenue, revenue growth, earnings per share, operating margin, operating cash flow, capital expenditures, capital allocation, growth
Slide 3: Agilent Results Q2'23
Agilent Results Q2’23 A leading lab partner with unsurpassed capabilities and scale Q2’23 Financial Metrics Q2’23 Highlights • Revenues: $1.72B, +6.8% reported, • Growth: Excellent results in Chemicals and Advanced Materials combined +9.5% y/y core(1)(2) (-2.8% FX,+0.1% M&A). with an outstanding per
Slide 4: Growth in a $68B+ Market – Q2'23 Core Growth Results by End Market
Growth in a $68B+ Market – Q2’23 Core Growth(2) Results by End Market Continued momentum in CAM supported by robust growth in Food and Academic & Government Pharma & Biotech: Up 6% with BioPharma strength offsetting softening demand in small molecule. Chemicals & Advanced Materials: Up 16% drive
Slide 5: Life Sciences & Applied Markets Group (LSAG)
Life Sciences & Applied Markets Group (LSAG) • Q2 core revenue growth of +10% for LSAG was driven Instrumentation, Informatics, and by strong performance in LC & LCMS and lab Consumables for Analytical Laboratories consumables. Asia saw outstanding growth in the mid- 20s, with especially strong perf
Slide 6: Agilent CrossLab Group (ACG)
Agilent CrossLab Group (ACG) • CrossLab continued to deliver Analytical Laboratory Services exceptional results in Q2, growing 13% core. The team’s ability to attach services to new-instrument installations while increasing additional offerings to the existing instrument base is driving market-leadi
Slide 7: Diagnostics and Genomics Group (DGG)
Diagnostics and Genomics Group (DGG) Pathology, Genomics, and • Q2 core revenue growth of 3% was led by NASD, Nucleic Acid Manufacturing Pathology, and Companion Diagnostics pharma services. • Launched an NGS Assay for Comprehensive Genomic Profiling (CGP) for advancing precision oncology. The SureS
Slide 8: Q3'23 and FY'23 Guidance and Forward-looking Considerations
Q3’23 and FY’23 Guidance and Forward-looking Considerations Based on Forecasted Exchange Rates Q3’23 Guidance (1) FY’23 Guidance (1) Low End High End Low End High End Net Revenue ($M) $1,640 $1,675 Net Revenue ($M) $6,930 $7,030 Y/Y Core Revenue Growth (2) -4.5% -2.5% Y/Y Core Revenue Growth (2) 3.0
Slide 9: Q2'23 Financial Results Overview
5/23/2023 Q2'23 Financial Results Overview